UNC Lineberger Comprehensive Cancer Center / University of North Carolina
Welcome,         Profile    Billing    Logout  
 72 Trials 
106 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carey, Lisa A
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EFZO-FIT, NCT05415137 / 2022-001012-26: Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Active, not recruiting
3
268
Europe, Japan, US, RoW
Efzofitimod 3 mg/kg, ATYR1923, KRP-R120, Efzofitimod 5 mg/kg, Placebo
aTyr Pharma, Inc., Kyorin Pharmaceutical Co.,Ltd
Pulmonary Sarcoidosis
07/25
08/25
HARMONIA, NCT05207709 / 2021-002027-38: Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Recruiting
3
456
Europe, US
Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
SOLTI Breast Cancer Research Group, Novartis, Alliance Foundation Trials, LLC.
Metastatic Breast Cancer
03/26
03/27
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
SSc-ILD, NCT05892614: Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD)

Recruiting
2
25
US
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
aTyr Pharma, Inc.
Interstitial Lung Disease
12/24
12/24
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
HARMONY, NCT03769415: Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Recruiting
N/A
500
US
Intrinsic Subtyping of Primary Breast Cancer
UNC Lineberger Comprehensive Cancer Center, Veracyte, Inc., Breast Cancer Research Foundation
Breast Cancer
12/30
12/30
Le, Linda Van
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
CAMPSTIM, NCT06449638: Modified Platform Trial Assessing Multiple CAMPs and SOC Vs SOC Alone in the Treatment of Hard-to-Heal DFUs

Recruiting
N/A
272
US
Standard of Care, Revita, Relese, Cogenex, Enverse
StimLabs, SerenaGroup, Inc.
Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
06/26
08/26
Adkins, Douglas
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
NCT04966481: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Recruiting
3
81
US
Palbociclib, Ibrance, Cetuximab, Erbitux
Washington University School of Medicine, Pfizer, The Joseph Sanchez Foundation
HPV-unrelated Head and Neck Squamous Cell Carcinoma
02/27
02/27
HexAgon-HN, NCT06295731: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting
2/3
410
US
INBRX-106, Hexavalent OX40 agonist antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/29
05/29
NCT02573493: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Completed
2
96
US
nab-Paclitaxel, Abraxane, Cisplatin, cis-DDP, cis-Platinum II, cis-Diamminedichloroplatinum, DDP, Cetuximab, Erbitux®, Intensity-Modulated Radiation Therapy, IMRT
Washington University School of Medicine, Celgene Corporation
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck
12/19
07/24
Los Tres Paso, NCT03389477: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
26
US
Palbociclib, Ibrance, PD 0332991, Cetuximab, Erbitux, Cisplatin, Platinol-AQ, Platinol, Intensity-Modulated Radiation Therapy, IMRT, Tumor biopsy, Peripheral blood draw
Washington University School of Medicine, Pfizer
Head and Neck Squamous Cell Carcinoma
02/22
04/27
NCT02296684: Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
67
US
MK-3475 (neoadjuvant), SCH 900475, Pembrolizumab, Keytruda, Surgery, Intensity modulated radiation therapy, IMRT, Image-guided radiation therapy, IGRT, Cisplatin, cis-DDP, cis-Platinum II, cis-Diamminedichloroplatinum, DDP, MK-3475 (adjuvant), Peripheral blood
Washington University School of Medicine, Merck Sharp & Dohme LLC
Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
04/22
12/25
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
CACTUX, NCT02270814: Cisplatin, Nab-Paclitaxel, and Cetuximab () in Patients With Incurable Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
74
US
nab-paclitaxel, Abraxane, Albumin-bound paclitaxel, Paclitaxel protein-bound, Cisplatin, Cisplatinum, CDDP, cis-DDP, cis-Diamminedichloroplatinum, cis-Platinum II, DDP, Carboplatin, Paraplatin®, CBDCA, Cetuximab, Erbitux®
Washington University School of Medicine, Celgene Corporation
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck
12/25
12/25
KEYNOTE-C34, NCT04811027 / 2021-000055-39: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Checkmark Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Oct 2021 - Oct 2021: Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Active, not recruiting
2
171
Europe, US, RoW
eftilagimod alpha, IMP321, efti, eftilagimod alfa, pembrolizumab (KEYTRUDA®), MK-3475
Immutep S.A.S., Merck Sharp & Dohme LLC
HNSCC
03/24
03/25
NCT05283226: Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination with Paclitaxel in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Recruiting
2
46
US, RoW
NRC-2694-A, Paclitaxel
NATCO Pharma Ltd.
Carcinoma, Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma
12/24
01/25
KEYCHAIN, NCT03383094: Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Recruiting
2
114
US
Pembrolizumab, Immunotherapy, Radiation therapy, Radiotherapy, Cisplatin, Chemotherapy
Loren Mell, MD, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
12/25
12/26
BA3021-002, NCT05271604: A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
290
US
Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab, Erbitux
BioAtla, Inc.
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
12/26
12/26
NCT04831320: Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Active, not recruiting
2
46
US
nab-paclitaxel, Abraxane, Nivolumab, Opdivo
Washington University School of Medicine, Bristol-Myers Squibb
Metastatic Head-and-neck Squamous-cell Carcinoma
12/25
09/26
NCT04852328: Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Recruiting
2
30
US
CUE-101
Washington University School of Medicine, Cue Biopharma
Oropharyngeal Squamous Cell Carcinoma
10/27
10/27
NCT04643379: Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Active, not recruiting
2
30
US
Olaparib, Lynparza, Pembrolizumab, Keytruda, Carboplatin, Peripheral blood draw
Washington University School of Medicine, Merck Sharp & Dohme LLC, Joseph Sanchez Foundation
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
11/25
11/26
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
Rambro2, NCT05980000: Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Recruiting
2
72
US
Ramucirumab, Cyramza, Pembrolizumab, MK-3475, Keytruda
Washington University School of Medicine, Eli Lilly and Company
Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
04/28
04/31
NCT02101034: PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1/2
96
US
Cetuximab, Erbitux®, PD 0332991, palbociclib
Washington University School of Medicine, Pfizer
Carcinoma, Squamous Cell of Head and Neck
06/20
11/23
KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Checkmark P1b data in combination with pepinemab for recurrent or metastatic HNSCC
Apr 2022 - Apr 2022: P1b data in combination with pepinemab for recurrent or metastatic HNSCC
Completed
1/2
49
US
pepinemab + pembrolizumab, KEYTRUDA®
Vaccinex Inc., Merck Sharp & Dohme LLC
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
07/24
07/24
NCT03650764: Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Hourglass Oct 2020 - Dec 2020 : From P1b trial in combination with Keytruda for metastatic HNSCC
Active, not recruiting
1/2
43
US
Ramucirumab, Cyramza, Pembrolizumab, Keytruda, EORTC QLQ-30, FACT H&N, Peripheral blood
Washington University School of Medicine, Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma
12/25
12/25
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
KURRENT-HN, NCT04997902: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
1/2
40
US
Tipifarnib, Alpelisib, BYL719
Kura Oncology, Inc.
HNSCC
07/25
07/25
NCT05813327: Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Recruiting
1/2
35
US
ADI PEG20, PEGylated arginine deiminase, Ifosfamide, ifex, Radiotherapy, Mesna, sodium 2-mercaptoethane sulfonate
Washington University School of Medicine, Polaris Group
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
01/26
01/28
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
NCT04624113: Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Terminated
1
13
US
Tazemetostat, Tazverik, Pembrolizumab, Keytruda
Washington University School of Medicine, Epizyme, Inc.
Head and Neck Squamous Cell Carcinoma
08/22
02/24
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
11/24
05/25
NCT05472506: Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Withdrawn
1
54
US
IK-175 + nivolumab
Ikena Oncology, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer, Neck Cancer, Head Cancer Neck, Neck Carcinoma
04/23
04/23
NCT03809624: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Terminated
1
160
US
INBRX-105 - PDL1x41BB antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
10/24
10/24
SRF114-101, NCT05635643: Study of CHS-114 in Participants With Advanced Solid Tumors

Hourglass Jan 2024 - Jun 2024 : Results from SRF114-101 trial for advanced solid tumors
Recruiting
1
47
US
CHS-114, toripaliamab, Loqtorzi
Coherus Biosciences, Inc.
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
02/26
02/26
NCT06163534: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

Recruiting
N/A
500
US
Tempus AI, AstraZeneca
Head and Neck Squamous Cell Carcinoma
03/28
03/28
Grilley-Olson, Juneko
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
Price, Katharine A
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
Hart, Lowell L
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NCT05275673: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Terminated
2
7
US
sapanisertib, CB-228
Calithera Biosciences, Inc
Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation
03/23
03/23
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
Dittus, Christopher
NCT04548648: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

Recruiting
2
16
US
Acalabrutinib, ACP-196, CALQUENCE
UNC Lineberger Comprehensive Cancer Center, AstraZeneca
Central Nervous System Lymphoma
02/28
02/33
NCT05498220: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
44
US
Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc.
Diffuse Large B-cell Lymphoma
08/28
08/28
AMC-105, NCT04139304: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Active, not recruiting
1
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
08/27
Zhou, Qi
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT05446883: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Recruiting
3
498
RoW
QL1706, Placebo, Paclitaxel injection, Cisplatin/Carboplatin
Qilu Pharmaceutical Co., Ltd.
METASTATIC CERVICAL CANCER
09/24
07/25
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
NCT06321068: BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Active, not recruiting
2/3
140
RoW
carboplatin, Bobei, Paclitaxel, Tesu, Recombinant humanized anti-PD-1 monoclonal antibody injection, BAT1308 injection
Bio-Thera Solutions
Endometrial Cancer
11/24
12/24
NCT06226350: A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

Completed
2
29
RoW
Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Shandong New Time Pharmaceutical Co., LTD
Cervical Cancer
12/23
01/24
AK112-203, NCT04870177: Study of AK112 in the Treatment of Advanced Gynecological Tumors

Active, not recruiting
2
270
RoW
AK112
Akeso
Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm, Endometrial Neoplasms
05/23
05/24
NCT04828616: Study of DP303c Injection in Patients With Advanced Ovarian Cancer

Not yet recruiting
2
104
RoW
DP303c injection, DP303c
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ovarian Cancer
07/23
07/24
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Withdrawn
2
177
RoW
Balstilimab, Balstilimab + Zalifrelimab
Agenus Inc., Betta Pharmaceuticals Co., Ltd.
Cervical Cancer
12/24
12/24
ACTION, NCT04236362: A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Recruiting
1/2
90
RoW
TQB2450, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gynecological Cancer
12/21
05/22
NCT05740215: Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Recruiting
1/2
158
RoW
F520, Lenvatinib
Shandong New Time Pharmaceutical Co., LTD
Solid Tumors
05/24
05/24
NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Terminated
1
56
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Platinum-resistant Ovarian Cancer
05/23
05/23
NCT06686745: Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Recruiting
1
130
RoW
SIM0508 Tablets, SIM0508 in combination with olaparib
Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd.
Advanced Solid Tumors
06/27
12/28
Dunn, Lara
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
NCT04722523: A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Recruiting
1
40
US
Cisplatin, Carboplatin, Docetaxel, Cetuximab, Cemiplimab, Surgical Resection of Primary +/- Neck Dissection, Post-operative radiation therapy, Paclitaxel, Taxol
Memorial Sloan Kettering Cancer Center, Regeneron Pharmaceuticals
Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
06/26
06/26
Li, Guiling
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Recruiting
2
58
RoW
MRG002
Shanghai Miracogen Inc.
Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
06/22
09/22
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Recruiting
2
108
RoW
Envafolimab+Lenvatinib, Envafolimab
3D Medicines (Sichuan) Co., Ltd.
Advanced Endometrial Cancer
03/25
10/25
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Recruiting
2
88
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer
06/26
12/26
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting
2
90
RoW
B013, Paclitaxel, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Platinum-resistant Recurrent Ovarian Cancer
12/26
12/26
TQB2102-II-05, NCT06798207: A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

Not yet recruiting
2
90
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gynecological Tumors
05/26
11/26
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Recruiting
2
460
RoW
HS-20089
Hansoh BioMedical R&D Company
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
12/25
12/27
PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting
1/2
380
RoW
PM8002
Biotheus Inc.
Malignant Neoplasm
11/25
11/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
NCT04718376: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Terminated
1
56
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Platinum-resistant Ovarian Cancer
05/23
05/23
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

Recruiting
1
350
US, RoW
IMP7068
Impact Therapeutics, Inc., Covance
Advanced Solid Tumors
04/23
08/23
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Recruiting
1
159
RoW
SI-B003
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Solid Tumor
06/25
06/25
NCT05866354: To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Completed
1
19
RoW
Tisotumab Vedotin
Zai Lab (Shanghai) Co., Ltd.
Solid Malignancies
11/23
11/23
SPH7485-101, NCT06487455: A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

Recruiting
1
170
RoW
SPH7485
Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumor
12/27
12/27
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
ADRX-0706-001, NCT06036121: A Study of ADRX-0706 in Select Advanced Solid Tumors

Recruiting
1
144
US, RoW
ADRX-0706
Adcentrx Therapeutics
Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
09/25
12/26
Asbury, Deonna
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
Zhang, Huifeng
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
Caldwell, Doris Ann
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
Patel, Shetal
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT04471415 / 2020-002770-27: Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated
2a
61
Europe, US, RoW
DRP-104, atezolizumab
Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
03/23
03/23
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
 

Download Options